MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
AstraZeneca PLC Total Shareholders Equity 2011-2026 | AZN
Annual Total Shareholders Equity AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 15.6 B | 14.6 B | 14 B | 16.6 B | 16.7 B | 18.5 B | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 B | 14 B | 16 B |
Quarterly Total Shareholders Equity AstraZeneca PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 39.3 B | - | 15.7 B | - | 15.6 B | - | 13.7 B | - | 14.6 B | - | 15.1 B | - | 14 B | - | 14.3 B | - | 16.6 B | - | 15.4 B | - | 16.7 B | - | - | - | 18.5 B | - | - | - | 19.6 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 39.3 B | 13.7 B | 17.6 B |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-506 K | - | -19.68 % | $ 18.4 M |  Canada |
 |
Aptorum Group Limited
APM
|
23.1 M | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
13.9 M | $ 1.02 | -0.49 % | $ 428 M |  Israel |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Aligos Therapeutics
ALGS
|
53.5 M | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
18.6 M | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Cara Therapeutics
CARA
|
20.9 M | - | -3.03 % | $ 260 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.44 | -5.88 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-95.5 M | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
84.5 M | - | - | $ 35.4 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
112 M | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |